[1] Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues[M]. International Agency for Research on Cancer (IARC), 2008.
[2] 蔡晓虹,冯达娜,赖文兴,等.62例骨髓增生异常综合征FAB和WHO分型及形态学特点[J].国际医药卫生导报,2021,27(14):2138-2140. DOI:10.3760/cma.j.issn.1007-1245. 2021.14.021.
[3] Cohen HJ. Prevalence of monoclonal gammopathy of undetermined significance[J]. N Engl J Med, 2006, 354(26):2832; author reply 2832. DOI: 10.1056/NEJMc061160.
[4] Kyle RA, Benson J, Larson D, et al. IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia[J]. Clin Lymphoma Myeloma, 2009, 9(1):17-18. DOI: 10.3816/CLM.2009.n.002.
[5] Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance[J]. N Engl J Med, 2018, 378(3):241-249. DOI: 10.1056/NEJMoa1709974.
[6] 许婧钰,王轶,邱录贵,等.多发性骨髓瘤遗传学异常和克隆演变[J].中国细胞生物学学报,2022,44(1):145-152. DOI:10.11844/cjcb.2022.01.0018.
[7] Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance[J]. Br J Haematol, 2006, 134(6):573-589. DOI: 10.1111/j.1365-2141.2006. 06235.x.
[8] Yoshida Y, Oguma S, Ohno H, et al. Co-occurrence of monoclonal gammopathy and myelodysplasia: a retrospective study of fourteen cases[J]. Int J Hematol, 2014, 99(6):721-725. DOI: 10.1007/s12185-014-1570-6.
[9] Nolte F, Mossner M, Jann JC, et al. Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects[J]. Eur J Haematol, 2017, 98(3):302-310. DOI: 10.1111/ejh.12827.
[10] 邢明泉,葛洪峰,吴维霞,等.1例老年骨髓增生异常综合征合并意义未明的单克隆免疫球蛋白血症并文献复习[J].老年医学研究,2022,3(3):27-30. DOI:10.3969/j.issn.2096- 9058.2022.03.007.
[11] 栗瑞敏,许玲,王菊美,等.骨髓增生异常综合征合并意义未明的单克隆免疫球蛋白血症1例诊治分析[J].南昌大学学报(医学版),2021,61(1):102-103,106. DOI:10.13764/j.cnki.ncdm.2021.01.023.
[12] 刘红娟,宋丽君,包慎.骨髓增生异常综合征合并意义未明的单克隆免疫球蛋白血症一例并文献复习[J].白血病•淋巴瘤,2021,30(2):111-113. DOI:10.3760/cma.j.cn115356- 20200331-00082.
[13] Roeker LE, Larson DR, Kyle RA, et al. Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients[J]. Leukemia, 2013, 27(6):1391-1393. DOI: 10.1038/leu.2013.34.
[14] Mailankody S, Pfeiffer RM, Kristinsson SY, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)[J]. Blood, 2011, 118(15):4086-4092. DOI: 10.1182/blood-2011-05-355743.
[15] 张炜,刘沁华,徐兴欣,等.单克隆丙种球蛋白病14例骨髓和肾脏活检病理分析[J].临床与实验病理学杂志,2022,38(6):702-707. DOI:10.13315/j.cnki.cjcep.2022.06.012.
[16] Lomas OC, Mouhieddine TH, Tahri S, et al. Monoclonal gammopathy of undetermined significance (MGUS)-not so asymptomatic after all[J]. Cancers (Basel), 2020, 12(6):1554. DOI: 10.3390/cancers12061554.
[17] Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant[J]. Blood, 2012, 120(22):4292-4295. DOI: 10.1182/blood-2012-07- 445304.
[18] 魏宇君,李新,申曼,等.肾意义的单克隆免疫球蛋白血症病例报道并文献复习[J].中国全科医学,2021,24(18):2359-2363. DOI:10.12114/j.issn.1007-9572.2021.00.410.
[19] 张婷.非恶性单克隆免疫球蛋白血症合并慢性肾脏病的临床分析[D].广州:南方医科大学,2021.
[20] Steiner N, Göbel G, Suchecki P, et al. Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients[J]. Oncotarget, 2017, 9(2):2344-2356. DOI: 10.18632/oncotarget.23412.
|
